Estimates Revisions Axsome Therapeutics, Inc. BOERSE MUENCHEN
Stocks
19X
US05464T1043
Pharmaceuticals
|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 190.35 EUR | +3.59% |
|
-2.91% | +42.83% |
| 09:35am | Axsome Therapeutics, Inc., Q2 2026 Earnings Call, Aug 10, 2026 | |
| 08:20am | Axsome Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AXSM Stock
- 19X Stock
- Consensus Axsome Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
